TUESDAY, Dec. 3, 2019 (HealthDay News) — Co-occurring psoriasis is common among patients with palmoplantar pustulosis (PPP), according to a study published in the November issue of the British Journal of Dermatology.
Yuki M.F. Andersen, from the University of Copenhagen in Hellerup, Denmark, and colleagues used administrative health care registries and insurance databases from the United States, Denmark, and Germany to identify patients with PPP and their use of antipsoriatic medication.
The researchers identified 1,435 U.S. patients, 751 Danish patients, and 1,832 German patients with PPP; estimated one-year prevalences were 0.009, 0.005, and 0.08 percent, respectively. Between 14.2 and 61.3 percent of patients with PPP had plaque psoriasis, and there was an overall higher prevalence of psoriatic arthritis among patients with co-occurring psoriasis. Similarly, medication use was more common in patients with PPP with co-occurring psoriasis, especially use of biologic therapies.
“We found that PPP had very low prevalence rates (<0.1 percent), confirming it as an orphan disease,” the authors write. “This study provides detailed information on the demographics and characteristics of this understudied patient population and adds to our understanding of the disease burden of PPP with or without co-occurring plaque psoriasis.”
Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which funded the study.
Abstract/Full Text (subscription or payment may be required)
Copyright © 2019 HealthDay. All rights reserved.
